The integrated safety data presented today includes data from the UPLIFT trial, a study that includes mortality as a pre-specified endpoint. UPLIFT (Understanding Potential Long-term Impacts on Function with Tiotropium), one of the largest COPD trials ever undertaken, involved 5,993 COPD patients from 37 countries around the globe over a four-year treatment period. Patient safety during the trial was closely followed by an independent Data Safety Monitoring Board.
The complete results of the UPLIFT trial will be presented on October 5th during the European Respiratory Society 2008 Annual Congress in Berlin.
About Spiriva(R) HandiHaler(R)
Spiriva HandiHaler is a once-daily inhaled maintenance prescription treatment for breathing problems (airway narrowing) associated with chronic obstructive pulmonary disease (COPD). COPD includes both chronic bronchitis and emphysema.
Spiriva does not replace fast-acting inhalers for sudden symptoms.
Do not swallow the Spiriva capsule. Only use the HandiHaler device to take the Spiriva capsule. Do not use the HandiHaler to take any other medications.
Do not get Spiriva powder in your eyes.
The most common side effect with Spiriva is dry mouth. Others include constipation and problems passing urine. For a complete list of reported side effects, ask your doctor or pharmacist.
Tell your doctor about your medicines, including eye drops, and illnesses like glaucoma and urinary or prostate problems. These may worsen with Spiriva.
If you have vision changes, eye pain, your breathing suddenly worsens, you get hives, or your throat or tongue swells, stop taking Spiriva and contact your doctor.
Do not use Spiriva if you are allergic to atropine, ipratropium, tiotropium bromide, or lactose. A lactose allergy is not the same as lactose intolerance.
Read the step-by-step Patient's Instructions for Use for Spiriva bef
|SOURCE Boehringer Ingelheim; Pfizer Inc|
Copyright©2008 PR Newswire.
All rights reserved